story of the week
Dalpiciclib Plus Letrozole or Anastrozole as First-Line Treatment for HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2023 May 11;[EPub Ahead of Print], P Zhang, Q Zhang, Z Tong, T Sun, W Li, Q Ouyang, X Hu, Y Cheng, M Yan, Y Pan, Y Teng, X Yan, Y Wang, W Xie, X Zeng, X Wang, C Hu, C Geng, H Zhang, W Li, X Wu, J Zhong, J Xu, Y Shi, W Wei, N Bayaxi, X Zhu, B XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.